Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMNIAOMS: Ozanimod in Multiple Sclerosis
NCT05777902Phase 4Terminated
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozanimod in multiple sclerosis (MS), sponsored by Fondazione Santa Lucia IRCCS. Started Jan 2023; status: terminated.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05777902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05777902.